Literature DB >> 28135567

TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.

Gordan Srkalovic1, Inga Marijanovic, Maya B Srkalovic, David C Fajgenbaum.   

Abstract

Castleman disease (CD) describes a group of three rare and poorly understood lymphoproliferative disorders that have heterogeneous clinical symptoms and common lymph node histopathological features. Unicentric CD (UCD) involves a single region of enlarged nodes. Multicentric CD (MCD) involves multiple regions of enlarged lymph nodes, constitutional symptoms, and organ dysfunction due to a cytokine storm often including interleukin 6. MCD is further divided into Human Herpes Virus-8 (HHV-8)-associated MCD, which occurs in immunocompromised individuals, and HHV-8-negative/idiopathic MCD (iMCD). Recently, iMCD has been further sub-divided into patients with TAFRO syndrome, which involves thrombocytopenia (T), anasarca (A), fevers (F), reticulin myelofibrosis (R), organomegaly (O), and normal or only slightly elevated immunoglobulin levels, and those who do not have TAFRO syndrome. Non-TAFRO iMCD patients typically have thrombocytosis, less severe fluid accumulation, and hypergammaglobulinemia. iMCD patients with TAFRO syndrome may have a worse prognosis, but more research is needed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28135567      PMCID: PMC5474112          DOI: 10.17305/bjbms.2017.1930

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  26 in total

1.  [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly].

Authors:  Kazue Takai; Koji Nikkuni; Hiroyuki Shibuya; Hideki Hashidate
Journal:  Rinsho Ketsueki       Date:  2010-05

2.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

3.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

Authors:  P S Moore; C Boshoff; R A Weiss; Y Chang
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

4.  Use of a claims database to characterize and estimate the incidence rate for Castleman disease.

Authors:  Nikhil Munshi; Maneesha Mehra; Helgi van de Velde; Avinash Desai; Ravi Potluri; Jessica Vermeulen
Journal:  Leuk Lymphoma       Date:  2014-09-29

5.  The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research.

Authors:  David C Fajgenbaum; Jason R Ruth; Dermot Kelleher; Arthur H Rubenstein
Journal:  Lancet Haematol       Date:  2016-03-17       Impact factor: 18.959

Review 6.  Multicentric Castleman's disease.

Authors:  B A Peterson; G Frizzera
Journal:  Semin Oncol       Date:  1993-12       Impact factor: 4.929

7.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

8.  Human herpesvirus 8-related Castleman disease in the absence of HIV infection.

Authors:  A Dossier; V Meignin; C Fieschi; D Boutboul; E Oksenhendler; L Galicier
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

9.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

10.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  9 in total

1.  Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.

Authors:  Sylvain Raoul Simeni Njonnou; Justine Deuson; Claire Royer-Chardon; Frédéric Alain Vandergheynst; Virginie De Wilde
Journal:  BMJ Case Rep       Date:  2020-06-30

2.  Castleman disease: Case series of two surgical patients from different ends of the disease spectrum with literature review.

Authors:  Radhika Raj C G; Suresh B
Journal:  Int J Surg Case Rep       Date:  2018-10-29

3.  TAFRO Syndrome - A Specific Subtype of Castleman's Disease in China.

Authors:  Wan-Lu Ma; Lu Zhang; Tie-Nan Zhu; Dao-Bin Zhou; Jian Li; Jian Sun; Bo-Ju Pan; Wei-Xing Xu
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

4.  Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.

Authors:  Yi Zhang; Shan-Shan Suo; Han-Jin Yang; Xin-Ping Zhou; Liang-Shun You; Wen-Juan Yu; Zhao-Ming Wang; Jie Jin
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-14       Impact factor: 4.553

Review 5.  Updates on the diagnosis and management of multicentric Castleman disease.

Authors:  Ya-Ju Wu; Kuei-Ying Su
Journal:  Tzu Chi Med J       Date:  2020-07-29

6.  Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.

Authors:  Qian-Yun Zhou
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

7.  Anti-interferon-γ Antibody-seropositive Disseminated Nontuberculous Mycobacterial Infection Mimicking POEMS and TAFRO Syndromes.

Authors:  Chiharu Hidekawa; Ryusuke Yoshimi; Daiga Kishimoto; Hideaki Kato; Masaki Mitsuhashi; Natsuki Sakurai; Yuichiro Sato; Takeaki Uehara; Yuki Iizuka; Takaaki Komiya; Naoki Hamada; Hideto Nagai; Yutaro Soejima; Reikou Kamiyama; Kaoru Takase-Minegishi; Yohei Kirino; Takuro Sakagami; Hideaki Nakajima
Journal:  Intern Med       Date:  2022-01-13       Impact factor: 1.282

8.  Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.

Authors:  Deanna E Morra; Sheila K Pierson; Dustin Shilling; Sepideh Nemat; Carlos Appiani; Mary Guilfoyle; Craig Tendler; Frits van Rhee; David C Fajgenbaum
Journal:  Br J Haematol       Date:  2018-09-11       Impact factor: 8.615

Review 9.  TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.

Authors:  Kun-Hua Tu; Pei-Yi Fan; Tai-Di Chen; Wen-Yu Chuang; Chao-Yi Wu; Cheng-Lung Ku; Ya-Chung Tian; Chih-Wei Yang; Ji-Tseng Fang; Huang-Yu Yang
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.